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Effects of Single-Dose Prucalopride 
on Intestinal Hypomotility in 
Horses: Preliminary Observations
Fulvio Laus1, Margherita Fratini1, Emanuele Paggi1, Vanessa Faillace1, Andrea Spaterna1, 
Beniamino Tesei1, Katia Fettucciari2 & Gabrio Bassotti3
Abnormalities of gastrointestinal motility are often a challenge in horses; however, the use of prokinetic 
drugs in such conditions must be firmly established yet. For this reason we carried out a preliminary 
study on the effects of prucalopride on intestinal motor activity of horses with gut hypomotility. 
The effect of prucalopride per os by oral dose syringe (2 mg/100 kg body weight) was assessed by 
abdominal ultrasound (evaluating duodenal, cecal, and colonic motor activity) in six horses with gut 
hypomotility. After administration of prucalopride, a significant increase of contractile activity was 
found in the duodenum at 30 minutes (p = 0.0005), 60 minutes (p = 0.01) and 90 minutes (p = 0.01), 
whereas in the cecum and in the left colon the increase was only present at 60 minutes (p = 0.03, and 
p = 0.02, respectively). No changes from baseline heart and respiratory rate or behavior side effects 
were observed after administration of the drug and throughout the observation period. Prucalopride 
may be a useful adjunct to the therapeutic armamentary for treating hypomotile upper gut conditions 
of horses. Dosing information is however needed to establish its actual clinical efficacy and its proper 
effects on the large bowel in these animals.
Gastro-intestinal motility abnormalities in horses can be due to several conditions including equine grass sick-
ness, gastroduodenal ulceration, intraluminal obstruction or impaction, excessive wall distention, strangulating 
obstruction, peritonitis, duodenitis, proximal jejunitis, colitis, and postoperative ileus (POI)1. The latter is respon-
sible for up to 86% equine deaths following abdominal surgery2.
Although several prokinetic drugs can be used in horses with gastrointestinal hypomotility, the use of these 
drugs is not well established yet3; bethanecol and neostigmine are cholinomimetic drugs that can be admin-
istered to horses, but are gravated by cholinergic side effects1, metoclopramide acts as a 5-hydroxytryptamine 
4-receptor (5HT-4) agonist, 5HT-3 receptor antagonist, dopamine 1 (DA1) and 2 (DA2) receptors antagonist1, and 
domperidone as a competitive antagonist at peripheral DA2 receptors, even though his efficacy in horses needs 
to be further investigated4. Other drugs with proven prokinetic effect in horses include erythromycin, naloxone 
and, in horses affected by POI, lidocaine administered as a starting dose of 1.3 mg/kg followed by 0.05 mg/kg/
min for 24 hours1. Cisapride is a second-generation benzamide that acts as a 5HT-4 agonist and 5HT-3 receptor 
antagonist; it can be used in managing persistent large colon impaction in horses, equine grass sickness, and as a 
preventative for POI1. However, due to serious cardiac side effects in humans this drug has been withdrawn from 
the market5 and it is presently difficult or impossible to find on the market, even for veterinary purposes.
Prucalopride is a dihydro-benzofurancarboxamide derivative approved in 2009 by the European Medicines 
Agency for the treatment of constipation in women6. Due to its selective high-affinity agonist effect for the sero-
tonin receptor 5-HT4, prucalopride stimulates gut motility and secretion via 5-HT4 receptor activation through 
enhanced release of acetylcholine7,8. Of interest, oral administration of the drug causes a rapid absorption from 
the gastrointestinal tract, with very high bioavailability (> 93%) that is not affected by food intake6,9. Although 
presently available for treatment of constipation, the available literature suggests that the enterokinetic proper-
ties of prucalopride may not be limited to the colon, but also involve the esophagus, the stomach, and the small 
bowel10.
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Unfortunately, data on the effects of prucalopride as enterokinetic in horses are limited to one in vitro study, 
showing that this drug failed to elicit an increase of submaximal electrical field stimulation-induced contractions 
in smooth muscle strips sampled from horses11. On the other hand, the presence of 5-HT4 receptors in the equine 
gut and the effectiveness of other selective 5-HT4 agonists has been repeteadly demonstrated12–14. To the best of 
our knowledge, no report on prucalopride administration in horses is available in literature, and in the present 
paper, the prokinetic effect of was tested in vivo for the first time in horses with intestinal hypomotility.
Methods
Six female standardbred horses (age 11 to 19, mean 15.0 ± 3.2 (SD) years, body weight from 383 to 512 Kg (mean 
458.2 ± 53.8 Kg)) presenting clinical manifestation of gastrointestinal diseases (inappetence, poor body condition, 
weight loss, mild colic) were referred to the Veterinary Teaching Hospital, School of Biosciences and Veterinary 
Medicine, University of Camerino.
All horses were affected by primary equine squamous gastric disease (ESGD) graded by gastroscopy as grade 
III or IV, according to the criteria proposed by Sykes and colleagues15. Hypomotility was assessed by auscultation 
and ultrasonography (see below) performed daily and did not improve after administration of metoclopramide 
(0.1 mg/kg subcutaneously every 8 hours for 48 hours). It was therefore decided to use prucalopride.
Motility of the descending duodenum, cecum, and left ascending colon (Fig. 1A–C) was assessed by ultra-
sonography, as previously described16,17. The three areas were clipped and cleaned with alcohol to obtain images 
as good as possible. Ultrasonography was performed with a curvilinear transducer at a frequency of 5 MHz 
(MyLabOne, Esaote, Italy). Briefly, the descending duodenum was imaged on the right side, from the 8th or 18rd 
intercostal space, along the line joining the olecranon and the tuber coxae, medially to the right lobe of the liver. 
The cecum was imaged in the dorsal part of the right paralumbar region. The left colon is normally viewed on all 
left wall but an acoustic window on the paralumbar region at level of the stifle was used.
Monitoring was started in the early afternoon, after the meal; a single dose of prucalopride (2 mg/100 kg body 
weight by oral dose syringe) was administered 40 minutes after the end of the meal and peristalsis was monitored 
before administration (basal) and at 5, 15, 30, 60, 90, 120, 180 and 240 minutes after administration of the drug. 
Water was available ad libitum. The drug dose was adapted from human studies, with this dose being a good com-
promise between effective pharmacologic action and paucity of side effects6.
The number of circular contraction in a cross sectional visualization was counted to assess duodenal motility. 
Deviation of cecal wall from the transducer was used to assess cecal contractions. For the left ascending colon 
changes in sacculation were considered, according to previously reported criteria17. For each anatomical location, 
intestinal contractions were counted during a 3-minute period.
Concerning clinical monitoring, behavioral patterns, heart and respiratory rates were assessed for every 
time-point used for ultrasonography (basal to 240 minutes).
All procedures were carried out in accordance with relevant guidelines and regulations and the experimental 
protocol was approved by the Institutional Animal Care and Use Committee of Camerino University (Protocol 
number 2/2016). All the horses’ owners gave written informed consent before enrollment.
Data analysis was carried out by means of the computer software program WINPEPI (PEPI-for-Windows)18. 
Mean and standard deviations were calculated for each measurement of contraction pre- and post- adminis-
tration of prucalopride. Differences in intestinal motility (number of contractions) among the time-points was 
evaluated by the ANOVA for repeated measures with Bonferroni’s correction, and the Student’s t-test with multi-
ple comparisons with the basal value after assessment of normal distribution by means of the Shapiro-Wilk test. 
Values of p < 0.05 were chosen for rejection of the null hypothesis.
Results
The overall results (expressed as mean ± SD) of contraction measurement in the three intestinal tract examined 
are reported in Table 1 and in Fig. 2.
Analysis of variance was statistically significant in the duodenum (F = 101.12, p < 0.0001) and in the cecum 
(F = 21.97, p = 0.002), but not in the colon (F = 1.77, p = 0.21), and the single comparisons with the basal val-
ues revealed significant differences at 30 minutes, (p = 0.0005), 60 minutes (p = 0.01) and 90 minutes (p = 0.01) 
for the descending duodenum, and only at 60 minutes for the cecum and the left colon (p = 0.03, and p = 0.02, 
respectively).
No signs of behavioral abnormality were registered during the study and no changes from baseline heart or 
respiratory rates were observed (Table 2).
Discussion
Due to possible species-related different intestinal sensitivity to 5-HT agonists, data on characterization and activ-
ity of these receptors in horses are to date conflicting.
For instance, stimulatory effects of 5-HT that were reduced by 5-HT3 and 5-HT4 receptor antagonists have 
been reported on circular and longitudinal muscle of equine ileum and pelvic flexure12, and a widespread 5-HT-4 
receptor immunoreactivity has been observed in all intestinal smooth muscle layers of duodenum, ileum and 
pelvic flexure sampled from healthy horses14. Moreover tegaserod, a 5-HT4 receptor agonist, stimulated large 
intestinal motility of horses in both in vivo13 and in vitro12,19, and increased the amplitude of smooth muscle 
contractions in a concentration-dependent manner on tissue preparations from duodenum and pelvic flexure 
sampled from healthy horses14. Another specific 5-HT4 agonist (mosapride) also increased myoelectric activity 
of equine jejunum in vivo20.
On the other hand, Delesalle and colleagues suggested that 5-HT receptors are not involved in contractile 
effect of serotonine in jejunum21, and in a recent preliminary report the same authors failed to find evidence for 
the presence of 5-HT4 receptors on the cholinergic neurons of the equine small intestine11. Other authors showed 
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Figure 1. (A) ultrasonographic visualization of the descending duodenum (arrows). RK: right kidney.  
(B) ultrasonographic visualization of cecum. (C) ultrasonographic visualization of left ascending colon (C) with 
typical sacculation. AW: abdominal wall.
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that the in vitro effects of 5-hydroxytryptamine (5-HT) and cisapride on the smooth muscle of horse are not 
altered by 5-HT4 antagonists, suggesting a primary non-cholinergic effect22, and that cisapride may modulate 
intestinal motility through a stimulation of nonserotonergic receptors23.
However, regardless of the mechanisms modulating intestinal contractions by means of 5-HT agonists, this 
class of drugs has proven to be active on intestinal motility of several species, including horses24–26.
Since prokinetic drugs are commonly used to treat intestinal dysmotilities in horses1,3,27, and the available 
data on current therapeutic approaches are (at least for some pathological conditions) still inconclusive28,29, there 
is the need for more targeted therapeutic approaches. Thus, in this preliminary study we evaluated the effects of 
Horse duodenum cecum colon
Time B 5 15 30 60 90 120 180 240 B 5 15 30 60 90 120 180 240 B 5 15 30 60 90 120 180 240
Mean 3.7 3.7 3.7 6.5* 6.3* 5.8* 3.7 4.0 3.7 1.0 1.0 1.5 1.3 2.2* 1.8 1.8 1.2 1.0 0.5 0.7 0.8 1.3 1.8* 1.0 0.8 0.7 0.8
sd 0.8 0.8 0.5 1.0 0.8 1.2 0.8 0.9 0.5 0.9 0.6 0.8 0.5 0.4 0.4 0.8 0.4 0.6 0.8 0.8 0.4 1.0 0.5 0.6 0.8 0.8 0.8
Table 1.  Mean and standard deviation of number of contraction/3 min of the examined tracts at different 
time-points; SD = standard deviation; *significant differences with basal value (B).
Figure 2. Ultrasonographic contractions recorded in the duodenum, cecum and colon in horses before 
(B = baseline) and after administration of 2 mg/100 Kg prucalopride. *statistically significant compared to B.
Time (mins) HR (mean ± SD) RR (mean ± SD)
B 34.3 ± 5.2 12.7 ± 1.2
5 35.0 ± 5.0 12.7 ± 1.8
15 34.5 ± 4.2 13.3 ± 1.2
30 34.2 ± 4.4 13.7 ± 1.9
60 34.3 ± 3.9 12.8 ± 1.5
90 34.3 ± 3.9 12.8 ± 1.2
120 34.8 ± 4.3 13.2 ± 1.2
180 34.5 ± 3.7 13.7 ± 0.8
240 33.7 ± 2.9 12.8 ± 1.7
Table 2.  Heart and respiratory rate after single-dose administration of prucalopride; SD = standard 
deviation. HR: heart rate; RR: respiratory rate (p = n.s. for all time intervals for both variables).
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prucalopride, a drug with proven intestinal prokinetic effects in humans and other animal species6,7, on intestinal 
motility of horses with gut hypomotility.
Our results showed that, 30 to 90 minutes after oral administration of prucalopride 2 mg/100 kg body weight, 
horses with postprandial intestinal hypomotility displayed an increased gut motor activity, maximal in the duode-
num, with only a minimal increase in the cecum and the left colon. Although we cannot explain these differences 
in the various tracts of the gastrointestinal system, it is possible that different receptor expression or different 
mechanism between intestinal segments may play a role. Of interest, although it is unknown whether enterocytes 
or other cells in the equine duodenum are equipped with 5-HT4 receptors, luminal application of prucalopride 
may have motor effects due to 5-HT4 receptors on epithelial cells (possibly enteroendocrine cells but also other 
epithelial cells)8. Alternatively, it is possible that the dose of the drug was too small to exert more important stim-
ulatory effects on the large bowel. Thus, even though this was a pilot trial conducted on a limited sample size, we 
feel these effects might be of clinical interest, and suggest that prucalopride could be tested in animals suffering 
from other forms of impaired motility such as intestinal impaction or postoperative ileus. The horses included 
in this study were in fact suffering from a chronic disease, for which it was not possible to have an immediate 
feedback on the improvement of clinical symptoms. However, prokinetics may be indicated to prevent colics that 
can be caused by hypomotility in horses affected by gastric ulceration15. Our results indicate that prucalopride 
could be used as supplement of specific therapy in horses affected by severe gastroduodenal ulceration causing 
intestinal hypomotility.
However, it must be taken into account the limit represented by the oral formulation of the drug, that cannot 
be always used, especially in horses with gastric reflux and in case of postoperative ileus. Moreover, the effects 
of repeated administrations of the drug are not known, and could provide insightful information on the actual 
propulsive effects of prucalopride-induced contractions in horses.
In this study we used ultrasonography to evaluate intestinal motor activity. Equine gastrointestinal motility is 
still poorly known, and it has been investigated using several techniques, including tissue culture, immunohisto-
chemistry, molecular biology, electrophysiology and whole animal studies30. The use of ultrasonography in this 
setting represents an important investigative tool, since it is non-invasive and it allows repeated measurements in 
the time course with objective measurements of intestinal contractions30.
In conclusion, in this preliminary study we have shown that a single-dose oral administration of prucalopride 
is able to improve upper postprandial intestinal motility in horses with gut hypomotility. Further studies, possibly 
also with dose-finding trials and randomized controlled conditions, are needed to establish whether prucalopride 
has prokinetic effects also on the equine large bowel, and whether this drug could be added to the therapeutic 
armamentarium of treatments for intestinal hypomotility in horses.
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